Mariah M. Kalmin

Mariah M. Kalmin

Auto-generated profile, based on publicly available information

Mariah M. Kalmin

Department of Behavioral and Policy Sciences, RAND Corporation, Santa Monica, CA, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in International Journal of Behavioral Medicine
Verified
Journal Article
Closed access
PDF file
MKMariah M. Kalmin
Mariah M. Kalmin
CNCandice Nicolo
Candice Nicolo
WLWahbie Long
Wahbie Long
DBDavid Bodden
David Bodden
LNLara Van Nunen
Lara Van Nunen
JIJonathan Ipser
Jonathan Ipser

18 March 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MKMariah M. Kalmin
Mariah M. Kalmin
DGDavid Goodman-Meza
David Goodman-Meza
EAErik Anderson
Erik Anderson
AAAriana Abid
Ariana Abid
MSMelissa Speener
Melissa Speener
AHAndrew A. Herring
Andrew A. Herring

26 July 2019 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
MKMariah M. Kalmin
Mariah M. Kalmin
EGEmily W. Gower
Emily W. Gower
ESElizabeth M. Stringer
Elizabeth M. Stringer
NBNatalie M. Bowman
Natalie M. Bowman
EMElizabeth T. Rogawski McQuade
Elizabeth T. Rogawski McQuade
DWDaniel Westreich
Daniel Westreich

9 April 2021 in AIDS
Verified
Journal Article
Closed access
MKMariah M. Kalmin
Mariah M. Kalmin
DWDaniel Westreich
Daniel Westreich
BDBradley M. Drummond
Bradley M. Drummond
JSJing Sun
Jing Sun
SMShruti H. Mehta
Shruti H. Mehta
GKGregory D. Kirk
Gregory D. Kirk
Objective: People with HIV (PWH) experience increased prevalence of obstructive lung disease (OLD), regardless of greater observed smoking behaviors. We investigated whether the effect of incident OLD on mortality differed by HIV and HIV viral suppression among persons who inject drugs (PWID) and report smoking history. Design: ALIVE is a longitudinal, observational cohort study of HIV-positive and seronegative PWID. This analysis included participants who had at least one spirometry measure to assess OLD between 2007 and 2016, excluding those who never smoked (5%, n = 62) or had baseline OLD (17%, n = 269). Methods: Incident OLD occurred when the first prebronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) less than 0.70 during follow-up. The effect of incident OLD on all-cause mortality was estimated in PWH and seronegative participants using inverse-probability-of-treatment-weighted marginal structural models controlling for baseline (age, race, sex, calendar year, smoking pack-years) and time-varying (smoking intensity, viral suppression, and calendar time) confounders. Results: Among 1204 participants, 269 (22.3%) and 157 (13.0%) experienced incident OLD and death, respectively, over a median of five person-years of follow-up. There was no effect of OLD on mortality among seronegative participants [hazard ratio = 0.84, 95% confidence interval (CI): 0.47–1.48]; however, PWH diagnosed with OLD experienced an increased mortality risk (hazard ratio = 1.71, 95% CI: 1.04–2.80) during follow-up. HIV viral suppression did not confound or modify the effect of OLD on mortality among PWH. Conclusion: There was an apparent effect of OLD on all-cause mortality irrespective of viral suppression among PWH but not among seronegative persons, after accounting for baseline and time-varying confounders. These results highlight the need for enhanced screening and management of OLD among PWH.

10 July 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ONOmar Nieto
Omar Nieto
ARAllison D Rosen
Allison D Rosen
MKMariah M Kalmin
Mariah M Kalmin
LLLi Li
Li Li
SSSteven J Shoptaw
Steven J Shoptaw
BTBengisu Tulu
Bengisu Tulu
Background: The United States is facing an opioid overdose epidemic resulting in an unprecedented number of preventable deaths. The use of medications including buprenorphine and methadone has proven effective for opioid use disorder (OUD), but many patients struggle to stay in treatment. Novel solutions, such as digital health tools, offer one option to help improve clinic management and improve treatment engagement. Objective: Using a mixed methods approach, we investigated facilitators and barriers to the use of a third-party digital health platform called Opioid Addiction Recovery Support (OARS) to aid OUD treatment engagement and adherence in a primary care setting. Methods: Patient and provider use of OARS was observed for 10 months and summarized using descriptive statistics. Differences in use were assessed using Wilcoxon signed rank tests. Additionally, key informant interviews were conducted with providers who prescribe medication for opioid use disorder (MOUD) and their case managers to understand the facilitators and barriers to implementation. Qualitative data were analyzed using a coding reliability thematic analysis approach. Results: Among 205 patients invited to use OARS, the median age was 37 (IQR 31-44) years, 130 (63.4%) identified as men, and 193 (94.1%) identified as non-Hispanic White. Of these 205 patients, 158 (77.1%) used the app at least 1 time. The median number of days the 158 patients viewed test results was 1 (IQR 1‐3), progress was 1 (IQR 0‐2), and educational content was 0 (IQR 0‐1). The 55 patients whose providers had manually entered their results into OARS when the electronic health record (EHR) integration failed viewed test results (P=.002), progress (P<.001), and educational content (P<.001) more days than the 103 patients who could not view their results in OARS. Providers and the lead case manager reported that OARS increased patient-provider communication, allowed patients to better track their overall MOUD treatment, and enhanced providers’ ability to identify patients at risk for relapse. They also acknowledged that the lack of integration between OARS with the EHR resulted in administrative burdens, which impacted provider use of the system. Conclusions: Findings from this study highlight the challenges of successfully implementing OARS with patients who receive MOUD in primary care settings. Our results show a lack of OARS uptake among providers, case managers, and patients, despite positive assessments made by participants. We also show several barriers that impacted provider use, including the lack of integration between OARS and EHR. Future research is needed (1) to determine whether digital health tools like OARS are efficacious in improving OUD outcomes and, if proved efficacious, (2) to identify ways to routinize the use of digital health tools in MOUD treatment, primarily by solving technical and organizational challenges associated with EHR integration and patient engagement.

18 August 2025 in JMIR Formative Research
Verified
Journal Article
Open access
ARAllison D Rosen
Allison D Rosen
SSSteven J Shoptaw
Steven J Shoptaw
LLLi Li
Li Li
BTBengisu Tulu
Bengisu Tulu
ONOmar Nieto
Omar Nieto
MKMariah M Kalmin
Mariah M Kalmin
Background: Medication-assisted treatment (MAT) is an effective strategy for treating opioid use disorder and reducing opioid-related overdose deaths, yet retention in treatment remains low. Mobile health (mHealth) platforms may be a useful tool for increasing long-term engagement in MAT programs, but evaluation studies of such platforms are limited. Objective: This study aimed to determine whether the use of the Opioid Addiction Recovery Support (OARS) software platform increased MAT engagement for patients with opioid use disorder. Methods: The Technology Improving Success of Medication-Assisted Treatment in Primary Care Study was a quasi-experimental study conducted at a primary care clinic in the United States between January 2021 and February 2022. OARS is a software platform and mobile app (Q2i, LLC) that includes a dashboard of real-time appointment attendance, urine toxicology (UTOX) results, and educational content as well as messaging and journaling features. All patients who were invited to use OARS and had available data across the study were included in the analysis. The primary outcomes were engagement in treatment, defined as no more than a 35-day gap in appointment attendance, and UTOX. Changes in treatment engagement between the treatment as usual (TAU) period and OARS intervention period were assessed using the effect size (Cohen g) and McNemar chi-square test of discordant pairs. Results: Among 205 patients invited to use OARS, 123 had available data and were thus included in the analysis. The median age was 37 (IQR 31‐42.5 ) years, 61% (75/123) identified as men, and 95.1% (117/123) identified as non-Hispanic White. There were no statistically significant differences in demographic characteristics for patients who used OARS on more than 1 day compared to patients who used OARS on 0 or 1 day, or patients who did versus did not have available data. Among all patients, 20% (25/123) were engaged in appointment attendance during TAU only compared to 27% (33/123) during OARS only (g=0.07; P=.36), and 13% (16/123) were engaged in UTOX during TAU only and 33% (41/123) during OARS only (g=0.21; P≤.01). Among a subsample of 52 patients who used OARS on more than 1 day, 17% (9/52) were engaged in appointment attendance during TAU only compared to 23% (12/52) during OARS only (g=0.07, P=.67), and 13% (7/52) were engaged in UTOX during TAU only and 35% (18/52) during OARS only (g=0.22, P=.05). Conclusions: Introduction of OARS in a primary care setting may be associated with a moderate change in MAT engagement as measured by UTOX, but not appointment attendance. While barriers to implementation and adoption, including difficulty fully integrating OARS with the clinic’s electronic health record, may have attenuated the potential effect of the intervention, this study provides evidence that mHealth interventions, such as OARS, are a promising addition to the MAT treatment landscape.